EVALUATION OF CSF NEUROFILAMENT LIGHT CHAIN LEVELS AS A ROUTINE BIOMARKER IN A MEMORY CLINIC

NIIKADO, MATÍAS; CALANDRI, ISMAEL; CHREM-MÉNDEZ, PATRICIO; MARTINETTO, HORACIO; CAMPOS, JORGE; PERTIERRA, LUCÍA; RUSSO, MARÍA JULIETA; ALLEGRI, RICARDO F.; SEVLEVER, GUSTAVO; SURACE, EZEQUIEL I.

Buenos Aires

Congreso; Reunión Conjunta de Sociedades de Biociencias; 2017

The revised diagnostic guidelines for Alzheimer?s disease recognize the potential use of biomarkers such amyloid beta, tau and phospho-tau. New biomarkers are currently under development to evaluate their utility in the diagnosis of different neurodegenerative diseases. In this work, we assessed the diagnostic performance of cerebrospinal fluid neurofilament light chain (NfL) in a clinical setting. A total of 51 patients with conditions frequently observed in a memory clinic and 11 cognitively normal individuals were evaluated. Clinical conditions included: Mild cognitive impairment (MCI, n=12), Dementia of Alzheimer´s Type (DAT, n=14), Behavioral variant Frontotemporal dementia (bvFTD, n=13), and logopenic (lvAPP, n=6), semantic (sAPP, n=2), and non-fluent (nfAPP, n=4) primary progressive aphasia (PPA) We quantified CSF NfL levels using a commercially available ELISA (IBL International). CSF NfL was significantly increased in MCI, FTD and DTA patients compared to controls (ANNOVA p